The estimated Net Worth of Paul Elliot Mann is at least $33.2 Million dollars as of 15 July 2024. Mr. Mann owns over 39,984 units of Abeona Therapeutics Inc stock worth over $32,677,055 and over the last 6 years he sold ABEO stock worth over $561,190. In addition, he makes $0 as Independent Director at Abeona Therapeutics Inc.
Sign up
Mr. Mann ABEO stock SEC Form 4 insiders trading
Paul has made over 14 trades of the Abeona Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 39,984 units of ABEO stock worth $223,511 on 15 July 2024.
The largest trade he's ever made was selling 132,664 units of Abeona Therapeutics Inc stock on 17 February 2021 worth over $310,434. On average, Paul trades about 14,873 units every 73 days since 2018. As of 15 July 2024 he still owns at least 5,845,627 units of Abeona Therapeutics Inc stock.
You can see the complete history of Mr. Mann stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Paul Mann biography
Paul Elliot Mann serves as Independent Director of the Company. Mr. Mann has over 20 years of experience in the financial and biotechnology industries. Most recently, he served as CFO at PolarityTE, Inc., a biotechnology and regenerative biomaterials company, where he was responsible for all financial operations. Prior to that, Mr. Mann was the Healthcare Portfolio Manager at Highbridge Capital Management and has held positions with Soros Fund Management, UBS Investment Group, Morgan Stanley and Deutsche Bank. Mr. Mann began his career as a scientist at Procter and Gamble and is named as an inventor on patents for skincare compounds and technologies. Mr. Mann has an MA (Cantab) and an MEng from Cambridge University where he studied Natural Sciences and Chemical Engineering.
How old is Paul Mann?
Paul Mann is 43, he's been the Independent Director of Abeona Therapeutics Inc since 2020. There are 6 older and 2 younger executives at Abeona Therapeutics Inc. The oldest executive at Abeona Therapeutics Inc is Jon Voss, 61, who is the VP & Head of Quality.
What's Paul Mann's mailing address?
Paul's mailing address filed with the SEC is C/O ASP ISOTOPES INC., 601 PENNSYLVANIA AVENUE NWSUITE 900, WASHINGTON, DC, DC, 20004.
Insiders trading at Abeona Therapeutics Inc
Over the last 16 years, insiders at Abeona Therapeutics Inc have traded over $4,486,735 worth of Abeona Therapeutics Inc stock and bought 427,809 units worth $1,765,143 . The most active insiders traders include Capital Partners Llc Rouhan..., Todd Wider, and Michael Amoroso. On average, Abeona Therapeutics Inc executives and independent directors trade stock every 50 days with the average trade being worth of $256,542. The most recent stock trade was executed by Mark Alvino on 17 June 2024, trading 25,890 units of ABEO stock currently worth $116,764.
What does Abeona Therapeutics Inc do?
abeona therapeutics inc. (nasdaq: $abeo), is a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases. abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases. abeona's lead programs include abo-102 (aav-sgsh), an adeno-associated virus (aav) based gene therapy for sanfilippo syndrome type a (mps iiia) and eb-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (rdeb). abeona is also developing abo-101 (aav-naglu) for sanfilippo syndrome type b (mps iiib), abo-201 (aav-cln3) gene therapy for juvenile batten disease (jncl), abo-202 (aav-cln1) for treatment of infantile batten disease (incl), eb-201 for epidermolysis bullosa (eb), abo-301 (aav-fancc) for fanconi anemia (fa) disorder and abo-302 using a novel crispr/cas9-based gene editing approach to gene t
What does Abeona Therapeutics Inc's logo look like?
Complete history of Mr. Mann stock trades at Abeona Therapeutics Inc, PolarityTE Inc, and Aspire Real Estate Investors
Abeona Therapeutics Inc executives and stock owners
Abeona Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Christine Silverstein,
Director -
Dr. Brendan M. O'Malley J.D., Ph.D.,
Sr. VP & Gen. Counsel -
Dr. Vishwas Seshadri M.B.A., Ph.D.,
Pres, CEO & Director -
Edward G. Carr,
Sr. VP, CFO & Chief Accounting Officer -
Todd Wider,
Independent Director -
Paul Mann,
Independent Director -
Michael Amoroso,
Chief Operating Officer -
Edward Carr,
Principal Financial Officer, Chief Accounting Officer, Vice President -
Alison Hardgrove,
VP of HR -
Joseph Walter Vazzano,
CFO, Principal Financial Officer & Principal Accounting Officer -
Sofia Warner,
Sr. Director of Investor Relations -
Jon Voss,
VP & Head of Quality -
Scott Nogi M.B.A.,
VP & Head of Bus. Operation -
Kristina Maximenko,
VP of HR -
Scott Santiamo,
Director of Corp. Communications -
Gregory Gin,
VP of Investor Relations & Corp. Communications -
Brian Kevany Ph.D.,
VP & Chief Technical Officer -
Mark Alvino,
Director -
Mark J Ahn,
Director -
Carsten Thiel,
Chief Executive Officer -
Timothy J Miller,
See Remarks -
George V Migausky,
Director -
B Davis Jeffrey,
Chief Operating Officer -
Stephen B Thompson,
VP-Finance Chief Acctg Officer -
Capital Management, L.P.Atc...,
-
Joao Md Siffert,
Chief Executive Officer -
Stephen B. Howell,
Director -
Steven H Rouhandeh,
Director -
Shawn Tomasello,
Director -
Stefano Buono,
Director -
Duyne Richard B Van,
Director -
Brian Jg Pereira,
Executive Chairman -
Capital Partners Llc Rouhan...,
-
Leila Alland,
Director -
Faith L. Charles,
Director -
Donald A. Wuchterl,
Director -
Brendan M. O'malley,
SVP, General Counsel -
Joseph Walter Vazzano,
Chief Financial Officer -
Bernhardt G Zeiher,
Director -
Eric Crombez,
Director